Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from TempraMed Technologies Ltd. ( (TSE:VIVI) ) is now available.
TempraMed Technologies has secured a Brazilian patent covering core innovations in its upcoming VIVI Box multi-medication storage platform, which is slated for market launch at the end of 2026. The patent strengthens the company’s protection of its thermal-insulation and smart-monitoring technology in one of the world’s largest healthcare and consumer markets, with term coverage through late 2039.
This grant reinforces TempraMed’s broader global intellectual property strategy, adding to recent patent wins in Asia and supporting commercialization across Latin America’s premium refrigeration sector. By underpinning features such as continuous temperature protection during power interruptions, portable cold storage, and cloud-based content tracking, the patent enhances TempraMed’s competitive positioning in home healthcare and digital health and supports its long-term goal of becoming a global leader in temperature-controlled medication management.
More about TempraMed Technologies Ltd.
TempraMed Technologies Ltd. is a global medical device company focused on temperature-controlled medication storage solutions for patients and healthcare providers. Its patented, FDA-registered thermal insulation devices, including VIVI Cap, VIVI Cap Smart, VIVI Epi, and VIVI Med, protect temperature-sensitive medications without batteries or external power across North America, Europe, and Asia.
Average Trading Volume: 41,889
Technical Sentiment Signal: Strong Sell
Learn more about VIVI stock on TipRanks’ Stock Analysis page.